Mohammad Razaq, MD
Hematology & Oncology · Oklahoma City, OKNPI 1710900337
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Merck at 55.5% of the total. Reporting peaked in 2019 at $18,012 and has fallen 85.7% since, to $2,569 in 2025. Among hematology & oncology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 373 payments — averaging $149.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$31K
- AstraZeneca$6K
- E.r. Squibb & Sons, L.L.C.$4K
- Incyte Corporation$4K
- Bristol Myers Squibb$3K
- Novartis$3K
- plus $5K from 49 others
Across 30 payments — averaging $7077.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$203K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- AbbVie$3K
- Merck$2K
- GSK$1K
- Bristol Myers Squibb$1K
What the payments were for
- Consulting fees$13,54224%
- Speaking & faculty fees$27,71550%
- Travel & lodging$5,40210%
- Food & beverage$6,30211%
- Education$5231%
- Other$2,1804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,664 in reported general payments places this provider in the 95th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 12 | $323,722 |
| KisqaliRibociclib Succinate | 18 | $295,393 |
| Lenalidomide | 20 | $293,532 |
| XtandiEnzalutamide | 17 | $219,887 |
| IbrancePalbociclib | 14 | $211,447 |
| VerzenioAbemaciclib | 13 | $188,258 |
| ErleadaApalutamide | 12 | $179,453 |
| NinlaroIxazomib Citrate | 13 | $169,515 |
| BrukinsaZanubrutinib | 12 | $168,511 |
| EliquisApixaban | 61 | $45,451 |
| Abiraterone Acetate | 14 | $34,800 |
| Ondansetron OdtOndansetron | 42 | $3,228 |
| Imatinib Mesylate | 13 | $3,222 |
| Letrozole | 145 | $2,670 |
| Megestrol Acetate | 21 | $1,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKOjjaara | $79 | $323,72212 claims |
| NovartisKisqali | $2,527 | $295,39318 claims |
| PfizerIbrance, Eliquis | $546 | $256,89875 claims |
| Astellas Pharma US IncXtandi | $155 | $219,88717 claims |
| Lilly USA, LLCVerzenio | $80 | $188,25813 claims |
| Johnson & JohnsonErleada | $136 | $179,45312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $166 | $169,51513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
- Charles HollenOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.